Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis

Table 5 Univariate survival analysis of the predictors of survival in study population

	Mean survival time (mo)	95%CI	Log-rank test	P value
Clinically significant portal hypertension
No	40.6	35.3-46	0.551	0.458
Yes	39.5	30.9-48.1
Preoperative AFP > 400 ng/mL
No	43.9	38.3-49.5	8.787	0.003b
Yes	24.6	14.1-35.2
Preoperative MELD score
< 10	46.38	41.13-51.63	19.209	< 0.001c
10-20	22.55	13.44-31.65
BCLC stage
0	51.9	40.5-63.2	22.328	< 0.001c
A	47.9	42.1-53.6
B	26.1	18.3-33.8
PHLF
No	47.1	41.4-52.8	8.489	0.004b
Yes	32.1	24.8-39.4
PHLF grade
Absent	47.1	41.4-52.8	114.117	< 0.001c
A	42.2	30.4-53.9
B	31.7	23-40.4
C	2.1	0.5-3.6
50-50 criteria
Absent	43.6	38.8-48.3	156.853	< 0.001c
Present	0.8	0.7-0.8
Post-operative MELD score
≤ 10	49.3	43.4-55.3	12.29	< 0.001c
> 10	32.7	25.8-39.7
Post-operative decompensation
No	52.2	47.1-57.4	27.716	< 0.001c
Yes	28.3	21.1-35.5
HCC recurrence
No	53.3	48.7-57.9	69.639	< 0.001c
Yes	13.2	9.6-16.8

^bP < 0.01.

^cP < 0.001.

AFP: Alpha-fetoprotein; BCLC: Barcelona clinic liver cancer; CI: Confidence interval; HCC: Hepatocellular carcinoma; MELD: Model for end-stage liver disease; PHLF: Post-hepatectomy liver failure.